Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Pfizer Limited, Ramsgate Road, Sandwich KENT, CT13 9NJ, UK
Fragmin 10,000 IU/4ml.
| Pharmaceutical Form |
|---|
|
Solution for injection for intravenous or subcutaneous administration. |
Active ingredient: Dalteparin sodium (INN).
Quality according to Ph Eur and in-house specification.
Potency is described in International anti-Factor Xa units (IU) of the 1st International Standard for Low Molecular Weight Heparin.
Content of active ingredient:
Fragmin 10,000 IU/4 ml: Ampoules containing dalteparin sodium corresponding to 2,500 IU (anti-Factor Xa)/ml.
| Active Ingredient | Description | |
|---|---|---|
| Dalteparin |
Dalteparin is an antithrombotic agent, which acts mainly through its ability to potentiate the inhibition of Factor Xa and thrombin by antithrombin. It has a relatively higher ability to potentiate Factor Xa inhibition than to prolong plasma clotting time (APTT). |
| List of Excipients |
|---|
|
Sodium chloride (Ph Eur) |
Clear glass ampoules (Ph Eur Type 1) containing dalteparin sodium, 10,000 IU (anti-factor Xa) in 4 ml.
Pfizer Limited, Ramsgate Road, Sandwich KENT, CT13 9NJ, UK
PL 00057/0978
27 March 2002 / 30 July 2007
| Drug | Countries | |
|---|---|---|
| FRAGMIN | Austria, Brazil, Canada, Germany, Estonia, Spain, Finland, Croatia, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
